The 36-month beta value for RVPH is at 0.04. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVPH is 22.96M, and currently, shorts hold a 4.61% of that float. The average trading volume for RVPH on April 19, 2024 was 313.29K shares.
RVPH) stock’s latest price update
The stock price of Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has dropped by -5.63 compared to previous close of 3.20. Despite this, the company has seen a fall of -20.32% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-28 that CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.
RVPH’s Market Performance
Reviva Pharmaceuticals Holdings Inc. (RVPH) has seen a -20.32% fall in stock performance for the week, with a 6.34% gain in the past month and a -25.80% plunge in the past quarter. The volatility ratio for the week is 8.42%, and the volatility levels for the past 30 days are at 9.74% for RVPH. The simple moving average for the past 20 days is -12.78% for RVPH’s stock, with a -30.10% simple moving average for the past 200 days.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at -18.66% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.35% of loss for the given period.
Volatility was left at 9.74%, however, over the last 30 days, the volatility rate increased by 8.42%, as shares surge +7.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.74% lower at present.
During the last 5 trading sessions, RVPH fell by -20.32%, which changed the moving average for the period of 200-days by -47.48% in comparison to the 20-day moving average, which settled at $3.47. In addition, Reviva Pharmaceuticals Holdings Inc. saw -41.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at 4.88. Equity return is now at value -435.38, with -184.22 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc. (RVPH), the company’s capital structure generated -0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -80.72. The debt to equity ratio resting at -0.03. The interest coverage ratio of the stock is -233.63.
Currently, EBITDA for the company is -24.11 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.38.
Conclusion
In conclusion, Reviva Pharmaceuticals Holdings Inc. (RVPH) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
